ResearcherInsermNo recent work listed
Bruno Robert
Matched on ORCID iD 0000-0001-5573-6945; OpenAlex author ID A5030911593. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 11
2014: 2 papers · 2015: 1 paper · 2016: none · 2017: none · 2018: 1 paper
Papers 4
- Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inhibits tumor growth in pre-clinical model… Co-author DOI 10.1016/j.canlet.2018.06.023↗
- Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the "TH… Co-author DOI 10.18632/oncotarget.3473↗
- Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy. Last author DOI 10.1038/onc.2013.487↗
- HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models. Co-author DOI 10.18632/oncotarget.2231↗
Closest collaborators
The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Christel Larbouret · 4 shared papers, 2014–2018 · strength 0.18
- Paper Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inh… DOI 10.1016/j.canlet.2018.06.023↗
- Paper Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after… DOI 10.18632/oncotarget.3473↗
- Paper Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy. DOI 10.1038/onc.2013.487↗
- André Pèlegrin · 4 shared papers, 2014–2018 · strength 0.18
- Paper Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inh… DOI 10.1016/j.canlet.2018.06.023↗
- Paper Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after… DOI 10.18632/oncotarget.3473↗
- Paper Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy. DOI 10.1038/onc.2013.487↗
- Gaëlle Thomas · 3 shared papers, 2014–2018 · strength 0.13
- Paper Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inh… DOI 10.1016/j.canlet.2018.06.023↗
- Paper Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy. DOI 10.1038/onc.2013.487↗
- Paper HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models. DOI 10.18632/oncotarget.2231↗
- Thierry Chardès · 3 shared papers, 2014–2018 · strength 0.13
- Paper Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inh… DOI 10.1016/j.canlet.2018.06.023↗
- Paper Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy. DOI 10.1038/onc.2013.487↗
- Paper HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models. DOI 10.18632/oncotarget.2231↗
- Pierre‐Emmanuel Colombo · 2 shared papers, 2014–2018 · strength 0.10
- Paper Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inh… DOI 10.1016/j.canlet.2018.06.023↗
- Paper HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models. DOI 10.18632/oncotarget.2231↗
- Wilhem Leconet · 2 shared papers, 2014 · strength 0.07
- Corinne Bousquet · 1 shared paper, 2018 · strength 0.06
- Charline Ogier · 1 shared paper, 2018 · strength 0.06
- Marc Ychou · 1 shared paper, 2015 · strength 0.04
- Eric Assénat · 1 shared paper, 2015 · strength 0.04
- Fabienne Portales · 1 shared paper, 2015 · strength 0.04
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.